274 reports of this reaction
1.4% of all RAVULIZUMAB reports
#19 most reported adverse reaction
HAEMOLYSIS is the #19 most commonly reported adverse reaction for RAVULIZUMAB, manufactured by Alexion Pharmaceuticals Inc.. There are 274 FDA adverse event reports linking RAVULIZUMAB to HAEMOLYSIS. This represents approximately 1.4% of all 19,021 adverse event reports for this drug.
Patients taking RAVULIZUMAB who experience haemolysis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOLYSIS is a less commonly reported adverse event for RAVULIZUMAB, but still significant enough to appear in the safety profile.
In addition to haemolysis, the following adverse reactions have been reported for RAVULIZUMAB:
The following drugs have also been linked to haemolysis in FDA adverse event reports:
HAEMOLYSIS has been reported as an adverse event in 274 FDA reports for RAVULIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOLYSIS accounts for approximately 1.4% of all adverse event reports for RAVULIZUMAB, making it a notable side effect.
If you experience haemolysis while taking RAVULIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.